Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.000
+0.020 (2.03%)
At close: Nov 20, 2024, 4:00 PM
0.970
-0.030 (-3.00%)
Pre-market: Nov 21, 2024, 8:56 AM EST

Company Description

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States.

The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.

It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications.

Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd
Tiziana Life Sciences logo
Country United Kingdom
Founded 2013
IPO Date Mar 24, 2000
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Gabriele Marco Cerrone

Contact Details

Address:
14/15 Conduit Street
London, W1S 2XJ
United Kingdom
Website tizianalifesciences.com

Stock Details

Ticker Symbol TLSA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001723069
CUSIP Number 88875G101
ISIN Number BMG889121031
SIC Code 2834

Key Executives

Name Position
Gabriele Marco Antonio Cerrone M.B.A. Founder, Executive Chairman and Interim Chief Executive Officer
Keeren Shah Chief Operating Officer and Chief Financial Officer
Dr. William A. Clementi Ph.D., Pharm.D. Chief Development Officer
Dr. Napoleone Ferrara M.D. Member of Scientific Advisory Board

Latest SEC Filings

Date Type Title
Nov 19, 2024 6-K Report of foreign issuer
Nov 1, 2024 6-K Report of foreign issuer
Nov 1, 2024 424B5 Filing
Nov 1, 2024 6-K Report of foreign issuer
Oct 30, 2024 6-K Report of foreign issuer
Oct 25, 2024 6-K Report of foreign issuer
Oct 25, 2024 424B5 Filing
Oct 18, 2024 6-K Report of foreign issuer
Sep 19, 2024 6-K Report of foreign issuer
Aug 19, 2024 6-K Report of foreign issuer